knowledge -WSS

knowledge

author：explore 2025-09-27 21:27:46 - browse：81

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Medicaid rebukes states for mistakenly disenrolling children

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

In areas with more Black doctors, Black people live longer

AstraZeneca chief proposes a novel edit to the drug pricing bill

#NeedHerScience: shining a light on gender disparities in medicine

ALS advocates say criticism of new drugs misses bigger picture

With FDA staff opposed to Sarepta therapy, top official intervened

hotspot

knowledge

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Moonlake's readout produced a cash windfall. Risks remain

Listen: Biogen's potential pivot, & Illumina's next chapter

In age of alternative facts, a scholarly course on calling out crap

How to fix cancer clinical trials' diversity problem

Anesthesiologist group: stop taking Ozempic before surgery

Why we need to separate burnout from moral injury in health care

Activists slam private health insurers over coverage restrictions

How to protect patients from sexual assault

entertainment

A rare thyroid diagnosis led to unexpected, all

Stem cell treatment guidelines are released by FDA

Trump surgeon general acknowledges mistakes during Covid

STAT's guide to the next generation of CAR

Humana sues Biden admin over Medicare Advantage audit rule

Ethical issues complicate the benefits of medical crowdfunding

leisure time

knowledge

Wikipedia

focus